Prostate Cancer - Results from #28060

Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: Active surveillance and focal targeted therapy - Abstract May 4, 2011

Results of vardenafil mediated power Doppler ultrasound, contrast enhanced ultrasound and systematic random biopsies to detect prostate cancer - Abstract May 4, 2011

EAU 2011 - The PCA3 score accurately predicts tumor volume and might help in selecting prostate cancer patients for active surveillance - Session Highlights May 4, 2011

EAU 2011 - Interest of early confirmatory biopsies and centralized pathological review to select prostate cancer patients for active surveillance - Session Highlights May 4, 2011

EAU 2011 - Non-invasive diagnosis of prostate cancer from body fluids using a panel of tumor suppressor genes - Session Highlights May 4, 2011

EAU 2011 - Evaluation of different molecular markers for the detection of minimal residual disease in lymph nodes of patients undergoing radical prostatectomy and extended pelvic lymph node dissection (PLND) - Session Highlights May 4, 2011

Small prostate size and high grade disease-biology or artifact? - Abstract May 3, 2011

Inhibition of prostate cancer using RNA interference-directed knockdown of platelet-derived growth factor receptor - Abstract May 3, 2011

A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer - Abstract May 3, 2011

Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer - Abstract May 3, 2011

Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: Evidence, rationale, and future directions - Abstract May 3, 2011

Computer-aided analysis of transrectal ultrasound images of the prostate - Abstract May 3, 2011

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting - Abstra May 3, 2011

Pathological findings after radical prostatectomy in men eligible for active surveillance (French trial SURACAP): Is the misclassification rate acceptable? - Abstract May 3, 2011

Editor's Commentary - Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study May 3, 2011

EAU 2011 - Open radical prostatectomy (ORP) performed by low volume surgeons predisposes to higher rates of venous thrombosis (VT) and pulmonary embolism (PE) - Session Highlights May 3, 2011

EAU 2011 - Influence of high dose low molecular weight heparin (LMWH) on blood transfusion and lymphocele rate in open radical prostatectomy - Session Highlights May 3, 2011

EAU 2011 - Combining screening and chemoprevention of prostate cancer - Session Highlights May 3, 2011

EAU 2011 - Results from the Gothenburg randomized prostate cancer screening trial - Session Highlights May 3, 2011

The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers - Abstract May 2, 2011

Page 1404 of 1435